Navigation Links
Burrill & Company CEO and Genzyme Executive Join BVGH Board of Directors

SAN FRANCISCO, Oct. 11 /PRNewswire-USNewswire/ -- BIO Ventures for Global Health (BVGH) announced today that G. Steven Burrill, Founder and Chief Executive Officer, Burrill & Company, and James A. Geraghty, Senior Vice President, Genzyme Corporation, have joined the organization's Board of Directors.  The addition of these two new board members rounds out the BVGH Board with a depth of expertise and experience in emerging markets and public-private partnerships.

"Both Steve Burrill and Jim Geraghty are long-standing colleagues in the biotech industry, deeply involved and widely respected," says Carl Feldbaum, Chair of BVGH's Board of Directors. "Their commitment and enthusiasm for biotechnology's increasing role in global health is beyond question. Our Board of Directors, staff, and donors are proud to have them now fully engaged in addressing the neglected diseases of the developing world."

Burrill founded Burrill & Company as a logical extension of his 40+ year involvement in the growth and prosperity of the biotechnology industry. Over the course of his career, Burrill has been an active advisor and catalyst to some of the industry's most well-known companies and transactions. Notably—prior to founding Burrill & Company in 1994—he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide.

In addition to his membership on BVGH's Board, Burrill currently serves as Chairman of the Boards of Pharmasset, Abunda Corporation, Foundation for the National Medals of Science and Technology, Vilas County Economic Development Corporation, and the World Council of Ethics.  He also serves as Chair of the San Francisco Mayor's Biotech Advisory Committee.  He is a member of the Boards of Directors of Catalyst Biosciences, DepoMed, NewBridge, Proventys, Targacept, and XDx. He serves as a member of the Board of various not-for-profit organizations including Bay Area Science Infrastructure Consortium (BASIC), The Kellogg Center for Biotechnology, the MIT Center for Biomedical Innovation, the National Health Museum, BioAg Gateway - City of Madison, University of Wisconsin College of Agriculture & Life Sciences, and the Scientific American Board of Advisors.

Geraghty is Senior Vice President of Genzyme Corporation and has played a leading role at the biotechnology company for over a decade.  He was President of Genzyme Europe from 1998-2002 and General Manager of Genzyme's cardiovascular business from 2003-2007.  He oversees Genzyme's strategic initiatives in emerging markets and has led many of the Company's largest transactions.  

Geraghty also oversees Genzyme's Humanitarian Assistance for Neglected Diseases program, under which Genzyme helps develop innovative therapeutic programs on a non-commercial basis. He has structured Genzyme's partnerships with Medicines for Malaria Venture, Brazil's Oswaldo Cruz Institute, and India's International Center for Genetic Engineering and Biotechnology. He served as Co-Chair of the Executive Committee for BIO 2007 and was a Steering Committee member of BVGH'S 2010 Partnering for Global Health Forum.  In addition to his membership on BVGH's Board, he serves as a Director of GTC Biotherapeutics (formerly Genzyme Transgenics Corporation), where he was Chairman and President and CEO, and of Bluebird Bio.

"Adding Steve Burrill and Jim Geraghty to our Board of Directors brings additional industrial and investor expertise to BVGH," says Melinda Moree, Chief Executive Officer of BVGH. "At a time when there is considerable activity in global health, it is critical that work aimed at incentivizing companies to work on new drugs, vaccines, and diagnostics for people in poor countries be grounded in the realities of companies and the investment community."

About BIO Ventures for Global Health

BIO Ventures for Global Health is a non-profit organization whose mission is to save lives by accelerating the development of novel biotechnology-based drugs, vaccines, and diagnostics to address the unmet medical needs of the developing world. The organization spurs biotech industry involvement in global health product development by increasing biotech and global health partnerships, designing and advocating for compelling market-based incentives, and synthesizing and disseminating critical information and quantitative analysis. For more information, please visit

SOURCE BIO Ventures for Global Health
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shawn Cross Joins Burrill Merchant Banking
2. Burrill & Company Invests in Taiwan Liposome Company
3. Joao Paulo Baptista Joins Burrill & Company
4. CEO of Burrill & Company to Speak at BioConference Live Slated for November 17th and 18th
5. Burrill & Company and WR Hambrecht + Co to Collaborate on OpenIPO(R) Transactions
6. Shawn Cross Appointed CEO of Burrill Merchant Banking Group
7. Burrill & Company Responds to Recent Press Coverage About Biopark Investment at Elk Run
8. CardioWest™ Artificial Heart Approved For Highest Reimbursement in CMS History : Plus Up To $53,000 New Technology Add-on Payments
9. 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis
10. Bruker Introduces HyperQuant™, a Unique Bench-Top NMR Reader to Quantify Hyperpolarization
11. Biotechnology & Drug Discovery Markets Push Up Demand for Lab Automation Products, According to a New Report by Global Industry Analysts
Post Your Comments:
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the launch of the Supplyframe Design Lab . Located in Pasadena, Calif., ... the future of how hardware projects are designed, built and brought to market. ...
Breaking Biology Technology:
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
Breaking Biology News(10 mins):